10x Genomics (NASDAQ:TXG) Given Equal Weight Rating at Stephens

10x Genomics (NASDAQ:TXG)‘s stock had its “equal weight” rating reiterated by equities researchers at Stephens in a report released on Friday, MarketBeat.com reports.

Other research analysts have also issued reports about the stock. Canaccord Genuity Group upped their price objective on shares of 10x Genomics from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Barclays upped their target price on 10x Genomics from $52.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a research report on Monday, September 21st. Royal Bank Of Canada started coverage on 10x Genomics in a research note on Tuesday, September 1st. They issued a “sector perform” rating and a $70.00 target price for the company. Finally, Citigroup lifted their price target on 10x Genomics from $45.00 to $50.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $68.00.

10x Genomics Stock Up 2.8%

Shares of 10x Genomics stock traded up $1.92 during trading on Friday, reaching $71.67. 976,352 shares of the stock were exchanged, compared to its average volume of 2,997,573. The firm has a market cap of $9.34 billion, a price-to-earnings ratio of -121.39 and a beta of 1.99. 10x Genomics has a 1 year low of $12.34 and a 1 year high of $102.81. The stock’s fifty day moving average is $72.18 and its 200 day moving average is $47.07.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.10. The business had revenue of $151.04 million during the quarter, compared to analyst estimates of $146.67 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. 10x Genomics’s quarterly revenue was down 12.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.28 EPS. Equities analysts forecast that 10x Genomics will post -0.75 earnings per share for the current year.

Insider Buying and Selling at 10x Genomics

In related news, Director John R. Stuelpnagel sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $61.75, for a total value of $1,235,000.00. Following the sale, the director owned 328,436 shares in the company, valued at $20,280,923. This represents a 5.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Adam Taich sold 46,388 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the completion of the sale, the chief financial officer directly owned 316,344 shares in the company, valued at $20,426,332.08. This trade represents a 12.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is currently owned by company insiders.

Institutional Trading of 10x Genomics

Institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC raised its holdings in 10x Genomics by 29.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 934 shares of the company’s stock worth $84,000 after acquiring an additional 215 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of 10x Genomics by 8.7% during the third quarter. GAMMA Investing LLC now owns 4,668 shares of the company’s stock valued at $422,000 after buying an additional 374 shares during the last quarter. Arizona State Retirement System boosted its position in shares of 10x Genomics by 1.5% during the second quarter. Arizona State Retirement System now owns 29,223 shares of the company’s stock valued at $1,120,000 after buying an additional 430 shares during the last quarter. Carolina Wealth Advisors LLC bought a new stake in 10x Genomics in the 3rd quarter worth about $46,000. Finally, Nisa Investment Advisors LLC increased its holdings in 10x Genomics by 11.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 6,239 shares of the company’s stock worth $564,000 after buying an additional 653 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.